S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:TVTX

Travere Therapeutics Stock Forecast, Price & News

$27.41
-1.78 (-6.10 %)
(As of 03/3/2021 03:59 PM ET)
Add
Compare
Today's Range
$27.40
Now: $27.41
$29.46
50-Day Range
$24.11
MA: $28.46
$31.77
52-Week Range
$8.98
Now: $27.41
$33.09
Volume57,817 shs
Average Volume690,286 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Travere Therapeutics logo

Headlines

Travere: 4Q Earnings Snapshot
March 1, 2021 |  finance.yahoo.com
Travere Therapeutics, Inc. to Host Earnings Call
March 1, 2021 |  finance.yahoo.com
A Preview Of Travere Therapeutics's Earnings
February 26, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TVTX
CUSIPN/A
CIKN/A
Phone(888) 969-7879
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$175.34 million
Book Value$5.15 per share

Profitability

Net Income$-146,430,000.00

Miscellaneous

Market Cap$1.40 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

762nd out of 1,968 stocks

Pharmaceutical Preparations Industry

370th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$27.41
-1.78 (-6.10 %)
(As of 03/3/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TVTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Travere Therapeutics (NASDAQ:TVTX) Frequently Asked Questions

Is Travere Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Travere Therapeutics?

Wall Street analysts have given Travere Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Travere Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Travere Therapeutics' next earnings date?

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Travere Therapeutics
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its quarterly earnings data on Monday, March, 1st. The company reported ($2.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $1.94. Travere Therapeutics had a negative net margin of 40.24% and a negative trailing twelve-month return on equity of 29.27%.
View Travere Therapeutics' earnings history
.

What guidance has Travere Therapeutics issued on next quarter's earnings?

Travere Therapeutics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51-51 million, compared to the consensus revenue estimate of $51.33 million.

What price target have analysts set for TVTX?

3 equities research analysts have issued twelve-month target prices for Travere Therapeutics' shares. Their forecasts range from $43.00 to $51.00. On average, they anticipate Travere Therapeutics' stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Travere Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:
  • Eric Dube, President, Chief Executive Officer & Director
  • Laura M. Clague, Chief Financial & Accounting Officer
  • Bill Rote, Senior VP, Head-Research & Development
  • Noah L. Rosenberg, Chief Medical Officer
  • Elizabeth E. Reed, Secretary, Senior Vice President & General Counsel

Who are some of Travere Therapeutics' key competitors?

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.45%), Janus Henderson Group PLC (8.00%), The Manufacturers Life Insurance Company (4.28%), Renaissance Technologies LLC (3.65%), Avoro Capital Advisors LLC (3.53%) and Dimensional Fund Advisors LP (2.33%). Company insiders that own Travere Therapeutics stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg and William E Rote.
View institutional ownership trends for Travere Therapeutics
.

Which institutional investors are buying Travere Therapeutics stock?

TVTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Avoro Capital Advisors LLC, Dimensional Fund Advisors LP, Nuveen Asset Management LLC, and Scopia Capital Management LP.
View insider buying and selling activity for Travere Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Travere Therapeutics?

Shares of TVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $27.41.

How much money does Travere Therapeutics make?

Travere Therapeutics has a market capitalization of $1.40 billion and generates $175.34 million in revenue each year. The company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

Where are Travere Therapeutics' headquarters?

Travere Therapeutics is headquartered at 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at (888) 969-7879 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.